Minimum prices of generic Hepatitis C Direct Acting Antivirals fall below US $50 per person cured

Hill, Andrew1; Hughes, Sophie2; Simmons, Bryony2; Cooke, Graham2; Khwairakpam, Giten3

1Liverpool University, Translational Medicine, Liverpool, United Kingdom
2Imperial College London, School of Public Health, London, United Kingdom
3AmFAR/Treat Asia Bangkok Thailand

Background: Worldwide in 2016, there were 1.6 million people cured of Hepatitis C (HCV) using Direct Acting Antivirals (DAAs), but 1.5 million new HCV infections. Elimination of HCV will only be possible by 2030 if at least 5 million people are cured each year. The World Health Organization has pre-qualified 3 generic forms of SOF and 2 formulations of DCV. Using data on exports of raw materials in 2015-2018, we calculated currently feasible generic prices of HCV DAAs, and compared to current national prices.

Methods: Data on per-kilogram prices of sofosbuvir (SOF), daclatasvir (DCV), ledipasvir (LDV) and velpatasvir (VEL) active pharmaceutical ingredients (API) exported from India were extracted from an online database (www.datamyne.com). All costs were calculated in US dollars ($). To calculate the cost of the amount of API needed for a 12-week treatment course, we added cost estimates for formulation ($0.01 per tablet), packaging ($0.35/month), and a profit margin of 26%. National prices were extracted from online price databases.

Results: The cost of exported SOF API has fallen from $10,100/kg in January 2015 to $970/kg in January 2018. Costs of API are currently $750/kg for DCV, $2250 for LDV and $9046 for VEL. The predicted minimum production price for SOF/DCV is now $48 per 12-week treatment course. Five generic formulations of SOF and four generic DCV have shown bioequivalence with originator drugs, by FDA criteria. As shown in Table 1, prices of generic SOF/DCV for public tenders in India are close to predicted minimum costs of production. Prices for sale to individuals in India are higher (Table 1). Prices of SOF/DCV in Egypt, Pakistan and Iran are also under $100 per 12-week course. By contrast, in high income countries, costs per 12-week course are approximately $8000 to $20,000, including discounts. Global sales of DAAs worldwide now total over $7 billion since launch.

Conclusions: The costs of generic production of HCV DAAs are falling rapidly. SOF/DCV combination treatment can now be produced for US$48 per patient per 12-week course. SOF/DCV is already on sale in India for $69 per cure. At these low prices, elimination of HCV worldwide could be feasible. Countries need to demand lower prices for HCV DAAs, to make elimination strategies affordable.